Can-Fite BioPharma (NYSE:CANF – Get Free Report) had its price objective hoisted by investment analysts at HC Wainwright from $2.50 to $5.00 in a research note issued to investors on Tuesday, Marketbeat reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 48.81% from the stock’s current price.
Can-Fite BioPharma Stock Down 4.3%
Shares of Can-Fite BioPharma stock opened at $3.36 on Tuesday. The firm has a market cap of $2.20 million, a PE ratio of -1.88 and a beta of 1.09. The business’s fifty day moving average is $3.44 and its two-hundred day moving average is $4.88. Can-Fite BioPharma has a fifty-two week low of $2.83 and a fifty-two week high of $23.40.
Institutional Trading of Can-Fite BioPharma
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers increased its holdings in shares of Can-Fite BioPharma by 42.4% during the 1st quarter. Rhumbline Advisers now owns 38,268 shares of the company’s stock worth $57,000 after buying an additional 11,388 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Can-Fite BioPharma during the 4th quarter worth $41,000. Finally, Sabby Management LLC increased its holdings in shares of Can-Fite BioPharma by 80.3% during the 3rd quarter. Sabby Management LLC now owns 1,406,050 shares of the company’s stock worth $871,000 after buying an additional 626,306 shares during the last quarter. 21.00% of the stock is currently owned by institutional investors and hedge funds.
Can-Fite BioPharma Company Profile
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.
The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).
Read More
- Five stocks we like better than Can-Fite BioPharma
- TMC Forges a New EV Supply Chain at the Bottom of the Sea
- Sell in May and Go Away—Starting With These 3 Stocks
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
